Equities

ImmuneOnco Biopharmaceuticals Shanghai Inc

ImmuneOnco Biopharmaceuticals Shanghai Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)14.58
  • Today's Change-0.12 / -0.82%
  • Shares traded123.20k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 14 2024 08:50 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in research and development of testing biotechnology. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)--
  • Net income in HKD--
  • Incorporated2015
  • Employees145.00
  • Location
    ImmuneOnco Biopharmaceuticals Shanghai IncSHANGHAI ChinaCHN
  • Phone+86 2 138016387
  • Websitehttp://immuneonco.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Beijing Luzhu Biotechnology Co Ltd0.00-268.53m4.09bn133.00--3.72-----1.34-1.340.005.43------0.00----------------6.41--0.0185------65.62------
Jiangsu Recbio Technology Co Ltd0.00-615.96m4.37bn472.00--3.76-----1.28-1.280.002.410.00----0.00-25.47---30.68----------2.33--0.378------20.86------
Microport NeuroTech Ltd-100.00bn-100.00bn4.38bn571.00------------------------------------------------21.61--768.73------
Ocumension Therapeutics265.32m-409.00m4.69bn444.00--1.49--17.67-0.6303-0.63030.40874.550.0783.612.12597,566.70-12.03-38.78-13.21-41.4758.6062.30-154.16-975.823.72--0.0451--54.99--5.68--319.66--
Shandong Boan Biotechnology Co Ltd665.68m-128.56m4.70bn813.00--3.30--7.05-0.2524-0.25241.312.790.27321.352.53818,795.40-5.28---7.02--66.16---19.31--0.8383-7.470.2491--19.80--64.02------
Consun Pharmaceutical Group Ltd2.79bn844.89m4.80bn3.13k5.391.185.161.721.061.063.494.820.49812.0810.05892,027.0015.1312.0422.5719.2574.1974.5530.3724.892.62--0.115540.8410.717.0314.8811.01-22.9318.43
Sihuan Pharmaceutical Holdings Group Ltd2.00bn-58.17m5.22bn2.87k--1.09--2.61-0.0063-0.00630.21550.51160.15720.81014.72697,655.80-2.18-6.85-3.34-9.1069.6475.81-13.85-36.231.35-2.630.1863---14.70-8.6097.23--0.9325--
Qyuns Therapeutics Co Ltd0.00-546.81m5.35bn331.00--16.86-----2.46-2.460.001.43------0.00----------------1.64-69.520.5349-------70.28------
ImmuneOnco Biopharmaceuticls Shanghi Inc-100.00bn-100.00bn5.46bn145.00-------------------------------------------------28.25--5.82------
Shanghai Fudan-Zhangjiang Bio-Pharm. Co871.49m110.05m5.78bn948.0017.490.7627--6.640.10690.10690.82762.450.28521.441.62919,288.803.597.034.359.0591.4092.1712.5917.263.94568.370.006239.16-17.502.78-21.28-0.632620.490.00
New Horizon Health Ltd1.47bn119.13m6.47bn1.04k59.322.0141.724.410.23840.23843.217.030.45362.162.081,670,567.003.67--3.99--88.74--8.10--10.50--0.1305--259.54--97.40------
Everest Medicines Ltd135.62m-909.43m6.58bn432.00--1.21--48.48-2.91-2.910.433216.760.02032.254.57313,934.60-13.63-30.52-15.06-33.1472.67---670.57-5,745.258.29--0.0979--884.46---241.50--4.65--
China Shineway Pharmaceutical Group Ltd4.86bn1.04bn6.60bn3.44k5.770.87115.401.361.381.386.449.160.50731.446.311,415,596.0010.898.0314.159.7775.1574.5521.4717.872.98--0.041136.2914.3211.9434.1413.890.639612.88
Ascentage Pharma Group International239.06m-996.84m6.69bn583.00--102.81--27.98-3.52-3.520.84680.22420.08332.382.22410,052.90-34.73-44.93-52.82-57.0486.2487.68-417.02-976.101.42-15.030.9622--5.85100.76-4.84--2.82--
Tong Ren Tang Technologies Co Ltd7.29bn635.59m6.75bn4.10k10.620.90974.940.92530.49630.49635.705.790.52120.98355.681,778,721.007.647.6812.1012.3242.0443.5014.6516.112.37--0.144339.9413.046.011.25-2.73-22.26-0.0089
Lepu Biopharma Co Ltd242.69m-23.80m7.34bn429.00--7.3794.4830.24-0.0143-0.01430.14630.58210.09171.061.62565,706.20-1.23---1.91--87.45---13.45--0.72010.13880.4549--1,347.16--96.79------
Data as of Jun 14 2024. Currency figures normalised to ImmuneOnco Biopharmaceuticals Shanghai Inc's reporting currency: Hong Kong Dollar HKD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.